Home » Stocks » CDXS

Codexis, Inc. (CDXS)

Stock Price: $21.24 USD -1.65 (-7.21%)
Updated Feb 25, 2021 4:00 PM EST - Market closed
After-hours: $21.25 +0.01 (0.05%) Feb 25, 6:29 PM
Market Cap 1.37B
Revenue (ttm) 66.67M
Net Income (ttm) -20.73M
Shares Out 59.06M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE 138.89
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $21.24
Previous Close $22.89
Change ($) -1.65
Change (%) -7.21%
Day's Open 22.54
Day's Range 20.84 - 22.99
Day's Volume 767,401
52-Week Range 8.43 - 29.56

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 11 hours ago

Shares of Codexis (NASDAQ:CDXS) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 500.00% year over year to ($0.06), which beat the ...

GlobeNewsWire - 12 hours ago

Strong Product Revenue Momentum in Second Half of 2020 Drives Company's Seventh Consecutive Year of YOY Revenue Growth

GlobeNewsWire - 1 week ago

REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will present at three upcoming virtua...

GlobeNewsWire - 2 weeks ago

REDWOOD CITY, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report fourth quarter and full year 2020...

GlobeNewsWire - 2 weeks ago

REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, announced today it will be expanding its operations into a new 36,000...

GlobeNewsWire - 3 weeks ago

REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to it...

GlobeNewsWire - 1 month ago

REDWOOD CITY, Calif. and HOFFMANN ESTATES, Ill., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes...

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced the pricing of an underwritten public offering of 4,...

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that it has commenced an underwritten public offerin...

GlobeNewsWire - 3 months ago

C ombine s Codexis' R&D and commercialization platform with Casdin Capital 's investment expertise to invest in and support innovative early stage life science and synthetic biology technology...

GlobeNewsWire - 3 months ago

REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate at three upcoming virtua...

Seeking Alpha - 3 months ago

Codexis, Inc. (CDXS) CEO John Nicols on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Codexis (CDXS) delivered earnings and revenue surprises of 37.50% and 22.85%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

REDWOOD CITY, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that it will report third quarter 2020 financial results ...

GlobeNewsWire - 5 months ago

REDWOOD CITY, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming virtual i...

The Motley Fool - 6 months ago

R&D revenue from two customers helped the business to offset weakness from the coronavirus pandemic.

Seeking Alpha - 6 months ago

Codexis, Inc. (CDXS) CEO John Nicols on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

REDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2020 financial resul...

Zacks Investment Research - 6 months ago

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Forbes - 8 months ago

Has the next biotech unicorn just been minted? Two California firms are focused on a radical new way of writing DNA to create everything from COVID-19 antibodies to high-density data storage.

GlobeNewsWire - 8 months ago

Partnership targets accelerating the commercialization of enzymatic DNA synthesis: Codexis invests cash and protein engineering for equity stake in Molecular Assemblies Partnership targets acc...

GlobeNewsWire - 8 months ago

REDWOOD CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, announces the election ...

GlobeNewsWire - 8 months ago

First enzymes will target NGS-based diagnostics, RNA-directed viral diagnostics and RNA manufacturing First enzymes will target NGS-based diagnostics, RNA-directed viral diagnostics and RNA ma...

The Motley Fool - 9 months ago

The company's largest source of revenue will be affected by the pandemic, but there appears to be a silver lining.

Seeking Alpha - 9 months ago

Codexis, Inc. (CDXS) CEO John Nicols on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

REDWOOD CITY, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the appointment of Stefan Lutz, ...

Zacks Investment Research - 9 months ago

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 10 months ago

The small-cap stock has been cut in half in the last year. Is a $650 million market cap too good to pass up?

GlobeNewsWire - 11 months ago

Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies Partnership to...

The Motley Fool - 11 months ago

The company expects a fourth straight year of stagnant product revenue -- and declining gross margin, to boot. Those are noteworthy red flags for investors.

The Motley Fool - 11 months ago

The enzyme engineering company reported disappointing full-year 2019 operating results.

Seeking Alpha - 11 months ago

Codexis, Inc. (CDXS) CEO John Nicols on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Codexis (CDXS) delivered earnings and revenue surprises of -66.67% and -11.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 11 months ago

The stock has tumbled to start 2020. Can the next business update provide any relief to shareholders?

The Motley Fool - 1 year ago

The company is developing a novel enzyme-based treatment for phenylketonuria (PKU), but it faces growing competition from potentially curative gene therapies.

GlobeNewsWire - 1 year ago

CHONGQING, China, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) today announced that it has attended the official opening of Porton Pharma Solutions Ltd.’s (SZSE: 300363) fe...

GlobeNewsWire - 1 year ago

REDWOOD CITY, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science,...

GlobeNewsWire - 1 year ago

REDWOOD CITY, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces a license agreement to provide Roche with Codexis’ EvoT...

The Motley Fool - 1 year ago

This favorite of institutional shareholders remains off the radars of most retail investors.

GlobeNewsWire - 1 year ago

REDWOOD CITY, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the publication with Merck, known as MSD outside the Un...

The Motley Fool - 1 year ago

Despite nearly meeting its full-year 2019 product revenue guidance after just three quarters, the company didn't raise guidance. What does that mean?

Zacks Investment Research - 1 year ago

Codexis (CDXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 1 year ago

Codexis, Inc. (CDXS) CEO John Nicols on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Codexis (CDXS) delivered earnings and revenue surprises of 166.67% and 32.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Forbes - 1 year ago

Big pharma has been slow to innovate and adopt the latest synthetic biology tools, which could vastly speed the creation of new treatments and vaccines. That is, until now, thanks in large par...

GlobeNewsWire - 1 year ago

Industry and academic leaders convened to discuss the direction of protein engineering for a wide range of applications Industry and academic leaders convened to discuss the direction of prote...

GlobeNewsWire - 1 year ago

REDWOOD CITY, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the 2019 Cantor Fitzge...

The Motley Fool - 1 year ago

Your money can buy more shares of these promising companies thanks to an affordable stock price.

Other stocks mentioned: SFIX, ZUO
The Motley Fool - 1 year ago

The enzyme engineering platform has $93 million in cash and no shortage of growth opportunities. Can it execute?

Seeking Alpha - 1 year ago

Codexis, Inc. (CDXS) CEO John Nicols on Q2 2019 Results - Earnings Call Transcript

About CDXS

Codexis discovers, develops, and sells protein catalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel b... [Read more...]

Industry
Biotechnology
IPO Date
Apr 22, 2010
CEO
John J. Nicols
Employees
161
Stock Exchange
NASDAQ
Ticker Symbol
CDXS
Full Company Profile

Financial Performance

In 2019, Codexis's revenue was $68.46 million, an increase of 12.98% compared to the previous year's $60.59 million. Losses were -$11.94 million, 9.72% more than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Codexis stock is "Strong Buy." The 12-month stock price forecast is 24.83, which is an increase of 16.90% from the latest price.

Price Target
$24.83
(16.90% upside)
Analyst Consensus: Strong Buy